|
Back to Home » August 2019 News » BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors |
BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors |
August 21, 2019
LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, today announced that the earlier communicated phase l/lla clinical trial...
Source URL: https://www.prnewswire.com:443/news-releases/bioinvent-will-conduct-phase-llla-trial-with-bi-1206-in-combination-with-pembrolizumab-keytruda-in-solid-tumors-300904973.html
|
|
|
|
